149 related articles for article (PubMed ID: 7908235)
1. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Seshi B; Kashyap A; Bennett JM
Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
[TBL] [Abstract][Full Text] [Related]
3. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
[TBL] [Abstract][Full Text] [Related]
4. A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: myeloperoxidase-positive and myeloid antigen-negative.
Specchia G; Mestice A; Clelia Storlazzi T; Anelli L; Pannunzio A; Grazia Roberti M; Rocchi M; Liso V
Leuk Res; 2001 Jun; 25(6):501-7. PubMed ID: 11337024
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia M2 and t(8;21)(q22;q22) with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-), and CD33(-).
García Vela JA; Martin M; Delgado I; García Alonso L; Monteserin MC; Benito L; Somolinos N; Oña F
Ann Hematol; 1999 May; 78(5):237-40. PubMed ID: 10391105
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
7. Cellular characteristics of acute leukemia cells simultaneously expressing CD13/CD33, CD7 and CD19.
Mizutani M; Miwa H; Takahashi T; Katoh K; Shikami M; Katayama N; Shiku H; Kita K
Int J Hematol; 1997 Dec; 66(4):479-91. PubMed ID: 9479874
[TBL] [Abstract][Full Text] [Related]
8. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
9. [Immunocytochemistry in the diagnosis of acute myeloid leukemia (M0)].
Saito M; Kuriyama K; Nagai K; Nonaka H; Hata T; Tusima H; Tabata S; Arimura K; Souda H; Nakamura H
Rinsho Ketsueki; 1994 Nov; 35(11):1297-304. PubMed ID: 7823396
[TBL] [Abstract][Full Text] [Related]
10. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
11. [The use of monoclonal antibodies for immunologic typing and prognosis prediction in acute non-lymphoblastic leukemia].
Chen GB; Tang MH; Yang TY
Zhonghua Nei Ke Za Zhi; 1993 Jun; 32(6):405-8. PubMed ID: 7903627
[TBL] [Abstract][Full Text] [Related]
12. [Application of flow cytometry in the differential diagnosis of lymphoma/leukemia with aberrant antigen expression].
Xia CQ; Chen SL; Qi M; Xu XF
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):532-5. PubMed ID: 15634450
[TBL] [Abstract][Full Text] [Related]
13. CD4 predicts nonlymphocytic lineage in acute leukemia. Insights from analysis of 125 cases using two-color flow cytometry.
Larson RS; McCurley TL
Am J Clin Pathol; 1995 Aug; 104(2):204-11. PubMed ID: 7543728
[TBL] [Abstract][Full Text] [Related]
14. The immunologic detection of minimal residual disease in acute leukemia.
Campana D; Coustan-Smith E; Janossy G
Blood; 1990 Jul; 76(1):163-71. PubMed ID: 1973061
[TBL] [Abstract][Full Text] [Related]
15. Surface marker expression in acute myeloid leukaemia at first relapse.
Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
[TBL] [Abstract][Full Text] [Related]
16. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy.
Xavier L; Cunha M; Gonçalves C; Teixeira Mdos A; Coutinho J; Ribeiro AC; Lima M
Leuk Lymphoma; 2003 Dec; 44(12):2137-42. PubMed ID: 14959860
[TBL] [Abstract][Full Text] [Related]
17. Value of monoclonal anti-myeloperoxidase (MPO7) for diagnosing acute leukaemia.
Storr J; Dolan G; Coustan-Smith E; Barnett D; Reilly JT
J Clin Pathol; 1990 Oct; 43(10):847-9. PubMed ID: 1977771
[TBL] [Abstract][Full Text] [Related]
18. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
[TBL] [Abstract][Full Text] [Related]
19. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms.
Nakase K; Kita K; Shiku H; Tanaka I; Nasu K; Dohy H; Kyo T; Tsutani H; Kamada N
Am J Clin Pathol; 1996 Jun; 105(6):761-8. PubMed ID: 8659452
[TBL] [Abstract][Full Text] [Related]
20. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
